TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02097823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Study: NCT01911416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Study: NCT04354935

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS basic
Description: 1 session per day, for 4 or 6 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS basic
Description: 1 session per day, for 4 or 6 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS basic
Description: 1 session per day, for 4 or 6 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS basic
Description: 1 session per day, for 4 or 6 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS VIIT
Description: 5 sessions per day, for 2 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS SAINT modified
Description: 8 sessions per day, for 1 week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS SAINT
Description: 10 sessions per day, for 1 week.
Study: NCT02511301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cyrcadia CBR™ device placement for abnormality screening
Description: Cyrcadia CBR™ device, including adhesive patches on both breasts connected to a small recorder, is placed on the study subject for 2 to 24 hours. After the test period, the CBR™ will be removed and the data will be downloaded to a central site for analysis. There are no interventions after the CBR™ is removed from the Study Subject.
Study: NCT02670369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting time prompt
Description: Participants will receive a device that prompts them to take breaks from sitting approximately every 15-20 minutes.
Study: NCT03082729

Intervention type: DRUG
Group type: OTHER
Intervention: Apremilast
Description: Apremilast (brand name Otezla) is a medication for the treatment of certain types of psoriasis and psoriatic arthritis.
Study: NCT01721538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight reduction program

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lecture on healthy nutrition
Study: NCT02672176

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Usual Care
Description: This program is a well-established program within the UC Davis Health System, providing care coordination to individuals with chronic conditions. Patients can self-refer or are referred by their providers for this service. The role of the care coordinator is to assess needs of the patient and coordinate healthcare referrals and appointments for the patient, facilitate communication among members of the healthcare team, identify health goals in collaboration with the patient and assist them in meeting those goals if requested by the patient. Contact is variable and conducted on a case by case basis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: P2E2T2 Program
Description: The P2E2T2 intervention group will receive Nurse Health Coaching using MI, an approach designed to elicit and support behavioral changes and improve self-efficacy (18-21). Nurses delivering the intervention will have completed the Health Science Institutes Registered Health Coach (RHC) training program (www.healthsciences.org). The intervention protocol is as follows:
Study: NCT01162044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer game
Description: Playing with specially designed computer game while in emergency room
Study: NCT04321772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Resistance Training
Description: Subjects trained one leg with HIIRT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Resistance Training
Description: Subjects trained the other leg with HIIRT
Study: NCT02696395

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DePuy Tri-Lock® femoral stem + Deltamotion® acetabular component

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DePuy Corail® femoral stem + Deltamotion® acetabular component
Study: NCT03117634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treat and Extend with Aflibercept 2mg
Description: Drug treatment regime which allows extension of treatment interval based on disease activity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fixed Dosing with Aflibercept 2mg
Description: Fixed 8 weekly dosing regime throughout the study duration
Study: NCT04052607

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LH Suppression
Description: Stimulation protocols

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LH Suppression
Description: Stimulation protocols

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LH Suppression
Description: Stimulation protocols
Study: NCT03541291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMART-SYNC LM03
Description: Doppler ultrasound cardiac gating device for fetal MRI application
Study: NCT02100839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEM-28
Description: Solution for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% saline for injection
Study: NCT03442725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: Oral administration of 1 tablet of Xermelo® containing telotristat etiprate equivalent to 250 mg telotristat ethyl.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: Oral administration of 1 tablet of Xermelo® containing telotristat etiprate equivalent to 250 mg telotristat ethyl.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telotristat etiprate
Description: Oral administration of 1 tablet of Xermelo® containing telotristat etiprate equivalent to 250 mg telotristat ethyl.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: Oral administration of 1 tablet of Xermelo® containing telotristat etiprate equivalent to 250 mg telotristat ethyl.
Study: NCT03440619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00013
Description: Investigational pulse oximeter device that will be placed on the subject's finger. This will be used as a spotcheck device
Study: NCT04389528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromodulation by tDCS
Description: The tDCS is a device for modulating cortical excitability. It consists of passing a low intensity direct electrical current over the scalp via two electrodes: an anode and a cathode soaked in a saline solution. Although there is a short-circuit effect through the scalp, a significant amount of electrical current enters the brain and changes the transmembrane potential.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Neuromodulation by tDCS
Description: The tDCS is a device for modulating cortical excitability. It consists of passing a low intensity direct electrical current over the scalp via two electrodes: an anode and a cathode soaked in a saline solution. Although there is a short-circuit effect through the scalp, a significant amount of electrical current enters the brain and changes the transmembrane potential.
Study: NCT00431093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tibolone
Description: uncoded tablets, at a dose of 2.5 mg per tablet; Subjects were to take 1 Livialâ tablet and 1 -matched Activelleâ placebo tablet, orally, once a day (preferably at the same time).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose estradiol/noresterone
Description: Activelleâ, estradiol (E2) 1 mg and norethisterone acetate (NETA) 0.5 mg per tablet, was supplied as uncoded tablets.~Subjects were to take 1 Activelleâ tablet and 1 Livialâ-matched placebo tablet, orally, once a day (preferably at the same time).
Study: NCT02490774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1007626
Description: Intrauterine device with 4 different in vitro release rates (low, low to medium, medium, high)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1007626
Description: Intrauterine device with 4 different in vitro release rates (low, low to medium, medium, high)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1007626
Description: Intrauterine device with 4 different in vitro release rates (low, low to medium, medium, high)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1007626
Description: Intrauterine device with 4 different in vitro release rates (low, low to medium, medium, high)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Jaydess
Description: Jaydess: Intrauterine device with a nominal in vitro release of 12 µg levonorgestrel/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirena
Description: Mirena: Intrauterine device with a nominal in vitro release of 20 µg levonorgestrel/day
Study: NCT00090896

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody
Study: NCT01557478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: 20 mg melatonin gelatin capsule (1) taken orally after 21:00 hours each night throughout the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: match placebo
Description: placebo gelatin capsule (1) taken orally after 21:00 hours each night throughout the study
Study: NCT03569098

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Investigators will inject the reconstituted solution into foot muscles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Investigators will inject the reconstituted solution into foot muscles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Investigators will inject the reconstituted solution into foot muscles.
Study: NCT01416545

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational program in cardiovascular prevention
Description: a weekly educational program in cardiovascular prevention with a multidisciplinary heath team during the year 2010. This intervention tried to teach to these children, in different manners appropriate for their age, concepts of healthy nutrition, avoidance of tobacco and physical activity. Both at the inclusion in the study and one year later we collect data of parents and their children of the two groups, in a single weekend, including nutritional and exercise survey, measures of weigh, height, waist circumference, arterial blood pressure, and laboratorial exams.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle counseling
Description: The control group received written educational material directed for their parents and related to healthy lifestyle (nutrition, exercise and smoke quitting).
Study: NCT00689962

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Linvatec 4.5 mm Smart Screw
Description: Linvatec 4.5 mm Smart Screw to surgically fix the foot's Lisfranc ligaments

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synthes 4.0 mm steel screw
Description: Standard steel screw use to surgically fix the foot's Lisfranc ligaments.
Study: NCT02892617

Intervention type: OTHER
Intervention: Bacteriological analysis of disc

Intervention type: OTHER
Intervention: Bacteriological analysis of disc
Study: NCT00616551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C2L-OCT-01 PR, 30 mg
Description: Administered by deep IM injection (gluteus) on days 1 and 42

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide acetate prolonged release, 30 mg
Description: Administered by deep IM (gluteus) on Days 1, 28 and 56
Study: NCT04069715

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng extract)
Description: A product made of highly concentrated pharmaceutical grade notoginseng root extract, and containing high potency bioactive components, notoginsenoside, ginsenoside Rb1, Rg1, Rd, Re and Rb2.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Turmeric 0.4%, Rice Flour 76.6%, Magnesium stearate 23%, capsule shell (gelatin) 61 mg
Study: NCT00334789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT04264780

Intervention type: OTHER
Intervention: Neuropsychological examination
Description: Neuropsychological follow-up examination, including questionaires

Intervention type: OTHER
Intervention: Neuropsychological examination
Description: Neuropsychological follow-up examination, including questionaires
Study: NCT02262650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Study: NCT00675987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan
Description: losartan 100 mg tablets 1 tab po QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Placebo 1 po QD
Study: NCT01795794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Study: NCT01450319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m\^2) every 2 weeks until disease progression, death, or consent withdrawal.
Study: NCT01613261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-733 and alisertib
Description: TAK-733 will be administered orally once daily (QD) on Days 1 through 14 of the 21-day cycle.~Alisertib will be administered orally twice daily (BID) on Days 1 through 7 of the 21-day cycle.
Study: NCT00823134

Intervention type: DEVICE
Group type: OTHER
Intervention: ApneaLink Plus
Description: Device used to evaluate for the presence of obstructive, central or mixed apneas
Study: NCT02192671

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic Resection
Description: Indications for HR are the presence of appropriate residual liver volume determined by volumetric computed tomography.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation
Study: NCT03756415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiMax Zero Total face mask R,
Description: a non-CO2 rebreathing device included directly in the full face mask

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: traditional face mask
Description: a traditional mask without a non-CO2 rebreathing device included directly in the full face mask
Study: NCT04575220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12 weeks of bicycle exercise
Description: Subjects will conduct monitored exercise, three sessions per week for 12 weeks.
Study: NCT01828970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basal-bolus detemir-aspart insulin regimen
Description: After the first CGM was completed during the conventional anti-diabetic treatment, patients received a rapid-acting insulin analogue before each meal (i.e., aspart) and a basal long-acting insulin analogue (i.e., detemir) once or twice daily. The analogues were titrated for optimal glycemic control. After one month of the aspart and detemir regimen, a physician adapted the insulin doses according to the glucose values observed from the second CGM.
Study: NCT00498680

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil, Vardenafil
Description: Sildenafil 100mg, vardenafil 20mg, combination of both half dosage.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 100mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vardenafil
Description: 20mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil & Vardenafil
Description: 50mg \& 10 mg
Study: NCT03434210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LAT-treated Community Model
Description: The subjects in experimental group is on 'LAT-treated Community Model'. which means,beside care as usual, subjects will be treated by paliperidone palmitate, Psychiatrists will guide community mental health professinals about the treatment and management. Psychiatrists will give community mental health professinals and patients/ caregiver long acting injection related education information.

Intervention type: OTHER
Group type: OTHER
Intervention: care as usual
Description: Control group will get usual community care, the treatment is identified by doctors, patients and care-giver as usual.
Study: NCT00699777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate
Description: 1 risedronate 150 mg tablet administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: 2 risedronate 75 mg tablets administered as a single oral dose
Study: NCT03547024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55308942 High Dose
Description: Participants will receive high dose of JNJ-55308942 orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55308942 High Dose
Description: Participants will receive high dose of JNJ-55308942 orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55308942 Low Dose
Description: Participants will receive low dose of JNJ-55308942 orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel/Ethinyl Estradiol Fixed Dose combination (FDC)
Description: Participants will receive 0.150 milligram (mg) levonorgestrel and 0.030 mg ethinyl estradiol FDC tablet orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Cocktail:Midazolam (2mg)/Omeprazole (20mg)/Dextromethorphan (30mg)
Description: Participants will receive single dose of drug cocktail consisting of midazolam (2 mg), dextromethorphan (30mg) and omeprazole (20 mg) orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Cocktail:Midazolam (2mg)/Omeprazole (20mg)/Dextromethorphan (30mg)
Description: Participants will receive single dose of drug cocktail consisting of midazolam (2 mg), dextromethorphan (30mg) and omeprazole (20 mg) orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Cocktail:Midazolam (2mg)/Omeprazole (20mg)/Dextromethorphan (30mg)
Description: Participants will receive single dose of drug cocktail consisting of midazolam (2 mg), dextromethorphan (30mg) and omeprazole (20 mg) orally.
Study: NCT02630862

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin is a standard and guidelines supported therapy for patients undergoing carotid endoarterectomy as secondary prevention measure of cardiovascular risk

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin plus dipyridamole
Description: the combination of aspirin plus dipyridamole is approved to lower the risk of stroke in people who have had a transient ischemic attack or stroke
Study: NCT02233218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study: NCT04318704

Intervention type: DRUG
Group type: OTHER
Intervention: Ifenprodil
Description: Ifenprodil 20 mg TID
Study: NCT02981030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Women seeking medical abortion will be offered the option to take mifepristone at home

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Women seeking medical abortion will be offered the option to take misoprostol at home. Misoprostol will be administered buccally.
Study: NCT01116921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (nCPAP)
Description: nCPAP equipment used in the trial will be the standard hospital equipment used in the NICU.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal continuous positive airway pressure (nCPAP)
Description: nCPAP equipment used in the trial will be the standard hospital equipment used in the NICU.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA) to deliver surfactant
Description: Laryngeal Mask Airway (LMA Unique-Size 1, The Laryngeal Mask Company Limited, San Diego, CA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surfactants, Pulmonary
Description: Curosurf®, Chiesi USA, Inc., Cary, NC
Study: NCT03429348

Intervention type: OTHER
Group type: OTHER
Intervention: Sauna Rehabilitation
Description: Firefighters selected for sauna rehabilitation will spend time in a sauna
Study: NCT03040167

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PEC 1 block
Description: Under echoguidance, injection of the substance of interest between the major and minor pectoral muscles.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEC 1 block
Description: Under echoguidance, injection of the substance of interest between the major and minor pectoral muscles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine with epinephrine
Description: Treatment group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo group
Study: NCT03504215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Assigned intervention : 14-week supervised intervention of aerobic and resistance training.
Study: NCT01298700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost 0.01% ophthalmic solution
Description: One drop of bimatoprost 0.01% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost 0.03% ophthalmic solution
Description: One drop of bimatoprost 0.03% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
Study: NCT02692586

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlowTriever System
Study: NCT04622917

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MethylPREDNISolone 40 Mg/mL Injectable Suspension
Description: intramuscular injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 9 MG/ML Injectable Solution
Description: Intramuscular injection